Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 121Carcinoma, Renal Cell 60Neoplasms 43Liver Neoplasms 42Neoplasm Metastasis 23Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 20Melanoma 18Kidney Neoplasms 16Breast Neoplasms 16Brain Neoplasms 13Pancreatic Neoplasms 12Sarcoma 11Prostatic Neoplasms 10Glioblastoma 10Lung Neoplasms 9Thyroid Neoplasms 8Recurrence 8Rectal Neoplasms 8Colorectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Colonic Neoplasms 7Stomach Neoplasms 6Ovarian Neoplasms 6Multiple Myeloma 6Leukemia 6Gliosarcoma 6Carcinoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Urinary Bladder Neoplasms 4

Interventions

Imatinib Mesylate 3nirogacestat 2vactosertib 1strattice 1entinostat 1Vinblastine 1Toremifene 1Taxes 1Tamoxifen 1Surveys and Questionnaires 1Sunitinib 1Sulindac 1Sorafenib 1Sirolimus 1Radiotherapy 1Nivolumab 1Methotrexate 1Fentanyl 1Data Collection 1Cyclophosphamide 1Blood Specimen Collection 1Albumin-Bound Paclitaxel 1Abdominoplasty 14-hydroxy-N-desmethyltamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Desmoid Tumors × Sorafenib × Clear all
NCT02066181 2023-06-07

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

National Cancer Institute (NCI)

Phase 3 Completed
87 enrolled 14 charts
Sarcoma

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡